Male Breast Cancer: 13-Year Single Institution Experience

Abstract

Due to the low incidence of male breast cancer (BC), there are few studies evaluating outcomes. We evaluated the clinicopathologic features and outcomes of male BC. Male patients with BC from January 2006 to December 2018 were identified. Of 49 patients, mean age was 64 (range 33-94) years. Of the 27 (55.1%) patients who had genetic testing, 9 (33.3%) had a Breast Cancer gene (BRCA) 1 or 2 mutation. The majority of patients had a mastectomy (n = 43/49, 87.8%) and had invasive ductal carcinoma (n = 47/49, 95.9%). 20 patients (n = 20/43, 46.5%) had positive lymph nodes. 41 (n = 41/47, 87.2%) patients had estrogen receptor positive disease. The majority of patients were pathologic stage 2 (n = 21/46, 45.7%), followed by stage 1 (n = 15/46, 32.6%), stage 3 (n = 6/46, 13.0%), and stage 4 (n = 4/46, 8.7%). Eight patients had the 21-gene recurrence score performed. Of patients with stage 1-3 BC, 10 (n = 10/43, 23.3%) patients had recurrence. With median follow-up of 4.1 (range .6-10.6) years, 5-year overall survival was 82.9% and 5-year disease-free survival was 65.9%. In conclusion, our cohort of patients with male BC had a high incidence of BRCA mutations and most commonly had high-grade estrogen positive stage 2 tumors. Breast conserving surgery was utilized in 4% of patients and genomic testing utilized in 55% of patients.

Management of patients with BRCA mutation from the point of view of a breast surgeon

“…Male breast cancer is rare, and they are more often BRCA mutation carriers compared to women, preferably BRCA2 mutations ([ 174 , 175 ]). In a publication including 49 men with breast cancer, 18.4% had a BRCA mutation [ 176 ].…”

Hemogram index parameters in the evaluation of male breast cancer and inflammatory response: a case-control study

“…The incidence of stage III/IV cancer at admission is >60% in Africa, <40% in North America and Western European countries, and between 40% and 60% in Eastern Europe and South America. The reasons for admission at later stages are reported to be race, low socioeconomic status, lack of awareness about the disease, and uncertainties in the characterization of highrisk patients for screening in the literature 8,[11][12][13][14][15][16][17] . In our study, the most common symptom was a breast mass, and 50% of them were at late stages at the time of diagnosis.…”

“…In the African literature, 61.5-88.9% and 46.5% of patients in developed countries have axillary lymph node metastases at the time of diagnosis 11,12,14 . Although breast-conserving surgery and SLNB are alternative options in the treatment of early-stage (stage 0/I/II) MBC, MRM is still the standard surgical treatment method in recent days 11,14,18,19 . In locally advanced (stage III) MBC, staged surgical mastectomy can be performed after preoperative systemic chemotherapy (10).…”

Breast Cancer in Men: A Systematic Review of the Literature from the Arab World

“…Since the HR positivity rate in the Arab world is comparable to the number in the US, the percentage of patients that benefited from hormonal therapy should be similar to that reported in the US. However, only 48 % of the patients in the Arab World Series benefited from this kind of treatments 80.9 % in the US [51] and 82.6 % in Portugal [52]. In contrast, there are more patients treated with radiations in the Arab world and Portugal with 66 % and 87 % respectively, than in the US where only 32.6 % benefited from radiations.…”